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Glycoprotein hormones (GPHs) are the most complex molecules with hormonal activity.
They exist only in vertebrates but the genes encoding their subunits’ ancestors are found
in most vertebrate and invertebrate species although their roles are still unknown. In the
present report, we review the available structural and functional data concerning GPHs and
their subunits’ ancestors.
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INTRODUCTION
Glycoprotein hormones (GPHs) are the most complex mole-
cules with hormonal activity. They include three pituitary hor-
mones, the gonadotropins follicle-stimulating hormone (FSH;
follitropin) and luteinizing hormone (LH; lutropin) as well as
thyroid-stimulating hormone (TSH; thyrotropin) (1). Only in pri-
mates (2) and equidaes (3), a chorionic gonadotropin (CG) is also
secreted by the placenta.
The GPHs exist only in vertebrates and appeared during evolu-
tion along with the pituitary. Nevertheless, genes coding for mol-
ecules related to GPHs subunits were identified in all vertebrates
studied and in most invertebrates (4–6).
The gonadotropins FSH and LH play a central role in ver-
tebrate reproductive function (7, 8) as they convey the inte-
grated central information from the hypothalamic–pituitary com-
plex toward gonads in both males and females. Indeed, inter-
nal (mainly endocrine) and external (photoperiod, congeners)
information are integrated at the hypothalamus level by pul-
satile gonadotropin-releasing hormone (GnRH) secretion. In
mammals, GnRH is released by GnRH neurons in the portal
hypothalamic–pituitary system through which it enters into the
anterior pituitary. In fishes, GnRH neurons release GnRH directly
into the pituitary. In all cases, GnRH stimulates the secretion
of both gonadotropins FSH and LH by the anterior pituitary
but their secretions are also differentially modulated by gonadal
feed-backs through the action of steroid hormones and protein
factors.
The TSH is also secreted by the antehypophysis but under the
control of the hypothalamic neuropeptide thyrotropin releasing
hormone (TRH) and is modulated by thyroid feed-back through
the action of thyroxin (T4) or tri-iodo-thyronine (T3).
The placental gonadotropins (hCG in human; eCG in the mare)
are secreted by trophoblast cells under no known control by any
releasing hormone.
In the present paper, we will consider the structure–function
relationships of GPHs and of their receptors (GPHRs) to better
understand their interactions and the subsequent steps in their
target cells stimulation.
STRUCTURE OF GLYCOPROTEIN HORMONES AND THEIR
ANCESTORS
Since 1971, GPHs are known to consist of two different glycopro-
tein subunits, called α and β, that are non-covalently associated
(9–12). This heterodimeric structure has been known for a long
time to be mandatory for their respective biological functions.
The saccharide part in GPHs represents as much as 20–45% of
their total mass (11, 13, 14) and has been shown to be indispensable
for their in vivo bioactivity (15, 16). It is therefore important to get
as much information as possible concerning both their polypep-
tide and polysaccharide portions as to decipher their respective
roles.
More recently, genes encoding for proteins related to the GPH
α and β subunits were found in both vertebrates and invertebrates
and were named GPA2 and GPB5, respectively (4, 6, 17) and are
considered as the molecular ancestors of GPH subunits (Figure 1).
Recombinant GPA2 and GPB5 have been produced using plasmids
encompassing the coding regions from these genes. These recom-
binant molecules were characterized using various immunoassays
and in vitro bioassays. The natural GPA2 or GPB5 proteins have
never been isolated but were detected in adult rat pituitaries by
immunohistology and western blotting using antibodies raised
against the recombinant proteins (6). The putative GPA2/GPB5
heterodimer has been described to exert thyrostimulating activity
(i.e., the name thyrostimulin coined for it) (6).
POLYPEPTIDE PART
The GPHs α- and β-subunits are encoded by different
genes (i.e., they do not originate from post-translational
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FIGURE 1 | Glycoprotein hormones’ emergence and evolution. The
GPH α- and β-subunits genes derived from GPA2 and GPB5 genes,
respectively after the two rounds of full genome duplication (2R) at the
origin of vertebrates (18). Both GPA2 and GPB5 are cystine-knot
proteins with three loops and might derive from the same ancestral
molecule.
proteolytic maturation of a unique precursor like insulin
subunits).
The α-subunits of all GPHs in a given species are encoded by a
same and unique gene that is expressed in pituitary gonadotrope
and thyrotroph cells of all vertebrates as well as in chorionic syn-
cytiotrophoblastic cells of primates and equidaes. Therefore, the
GPHs α-subunits all exhibit the same amino-acid sequence in a
given species.
By contrast, the β-subunits are different and specific for each
hormone. Therefore, there are at least three genes encoding β-
subunits in all vertebrate species, namely FSHβ, LHβ, and TSHβ.
In the human species, there are not only one but several genes
encoding the hCGβ subunit.
The two subunits are thus co-translated and they non-
covalently combine in the endoplasmic reticulum of gonadotrope
(FSH, LH), thyrotroph (TSH), or trophoblast (CG) cells. No infor-
mation is available for the time being concerning the natural GPA2
and GPB5 proteins.
Primary structure
All GPH subunits sequences as well as those of GPA2 and GPB5
exhibit a signal peptide at their N-terminus indicating that all these
molecules are secreted glycoproteins.
The common α-subunits (GPA1) of mammalian GPHs after
excision of their signal peptide exhibit 92 or 96 amino-acid
sequences among which 10 are cysteine residues. Since no cysteine
residue is in the reduced state, the α-subunits possess five disulfide
bridges (Figure 2). In other species, the maturated α subunits also
count approximately 90–100 amino-acid residues (19).
The amino-acid sequences of α-subunits are very well con-
served among vertebrate species and in particular the positions
of the 10 cysteine residues. The residues are found in groups of
two or three along the sequence leaving three sequence portions
without cysteines that are expected to form loops.
In the α-subunits, two potential N-glycosylation amino-acid
sequences (Asn–X–Ser/Thr) are found and both of them are
indeed occupied by oligosaccharide chains.
The amino-acid sequences of common α-subunits from all
vertebrates exhibit a fairly high percentage of identity. This is
well illustrated by the fact that it is possible to recombine these
α-subunits with β-subunits from the other GPHs and from
phylogenetically distant species (20, 21).
The GPA2 amino-acid sequences derived from the gene
sequences in numerous species indicate that there are two poten-
tial N-glycosylation sites but one is not at the same location as in
α-subunits.
The specific β-subunits (FSHβ, LHβ, TSHβ, and CGβ)
polypeptide sequences exhibit around 105–150 amino-acids (19).
Although different, the β-subunit amino-acid sequences exhibit
large similarities which are probably largely due to their main
common characteristic which is to associate with a common
α-subunit. The conserved sequences in the β-subunits are impor-
tant for (1) direct interaction with α and (2) similar global
folding.
All β-subunits possess 12 cysteine residues which are all impli-
cated in the six intra-chain disulfide bridges. In spite of their
different sequences that determine the specificity of the different
hormones, the β-subunits share a number of common features.
In particular, the positions of the 12 cysteine residues in their
sequences are highly conserved so that they are expected to share
a common global folding (see below). The repartition of cys-
teines along the amino-acid sequences of β-subunits also leaves
sequences without cysteines that are expected to form three loops
(L1, L2, L3).
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FIGURE 2 | Glycoprotein hormone α- and β-subunits’ primary structures. The relative positions of Cys residues and N- and O-saccharide chains along the
amino-acid sequences are shown.
Some mammalian β-subunits (hCGβ, eCGβ, and eLHβ) pos-
sess an extension of approximately 30 amino-acid residues at
their C-terminus that is called carboxy-terminal peptide (CTP).
This extension has of course occurred independently in primates
and equidaes through stop codon frameshift mutations leading
to readthrough of the previously untranslated 3′ downstream
nucleotide sequence (22, 23).
The GPB5 amino-acid sequences derived from their gene
sequences show that this molecule is shorter than β-subunits by
approximately 15–20 residues and misses cysteine residues III and
XII present in β-subunits (Figure 2).
All GPH β-subunits possess one or two potential N-
glycosylation amino-acid sequences (Asn–X–Ser/Thr), which are
found in conserved positions among the different species. The
GPB5 amino-acid sequences derived from the gene sequences
in numerous species indicate that there is one potential N-
glycosylation site but at a different location than in β-subunits.
Secondary structure
The circular dichroism (CD) analyses of GPHs had shown a long
time ago that they exhibit a limited amount of periodic (sec-
ondary) structures: only ~4–8% α-helix and ~30% β-sheet and
β-turn (24–30). From these data, the rest of the molecule was
expected to be non-periodic. Interestingly, the combination of
subunits was paralleled by an increase inβ-structure as determined
by CD (31, 32).
The three-dimensional (3D) structure of hCG determined by
X-ray diffraction (33, 34) confirmed the low amount of α-helix
but the proportion of β-sheet and β-turn appeared more impor-
tant than expected from CD data. Indeed, a very large β-sheet
involves sequences from both subunits and this structure is sus-
pected to be important for their heterodimerization. It is likely
that the increase in β-structure as determined by CD is due to
the formation of this common larger β-sheet involving peptide
portion from both subunits.
A possible explanation for the difference in β-structure pro-
portion as determined by CD and X-ray diffraction is that the first
one is carried out in solution whereas the second is performed
in crystals. It has been shown by hydrogen isotope exchange that
gonadotropins exhibit a highly mobile conformation in solution
(35). It is likely that this structural dynamics observed in solution
is restrained inside the crystal.
Tertiary structure
The folding of hCG subunits (tertiary structure) has been deter-
mined by X-ray diffraction (33, 34, 36). The determination of
this 3D structure has also permitted to find out the pairings of
cysteines in each of the 11 disulfide bridges (5 in α; 6 in β).
An outstanding structural feature has been discovered concern-
ing disulfide bridges: three of them in α and three of them in
β form a cystine-knot with similar pairings (Figure 2) (37–39).
In each cystine-knot, a disulfide bridge passes through the frame
formed by two other parallel disulfide bridges joining two amino-
acid sequence stretches. Such a structure, found only in a limited
number of proteins including TGFβ family (TGFβ, BMPs, activin,
inhibin, etc.) (39), is highly stable and forms the core of the 3D
folding of the two subunits (37, 38). In the 3D structure, the
three loops in α-subunits and the three loops in β-subunits can
be observed that extend from the cores of each subunit.
Quaternary structure/heterodimerization
The quaternary structure of glycoprotein consists of heterodimer-
ization of one α-subunit (common) with one of the specific
β-subunits. In the association of the two subunits, the L1 and
L3 loops of one subunit is aligned with the L2 loop of the other
(33, 34). As previously stated, a large β-sheet structure formed by
complementary regions from the α- and β-subunits is probably
responsible for their non-covalent association.
Association–dissociation equilibrium constants of GPH sub-
units were found to be around 10−7–10−6 M (40, 41). These values
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are much higher than the GPH physiological circulating concen-
trations (10−11–10−9 M) and therefore the hormones should be
totally dissociated and inactive at these concentrations. In fact, it
has been shown a long time ago that GPH integrity in vivo is a
kinetically regulated process (41), i.e., the equilibrium is reached
very slowly giving enough time for the heterodimer to exert its
action. This view has been validated later when the “seatbelt”
structure was discovered. Indeed, an outstanding feature of this
quaternary structure is that a sequence portion of the β-subunit,
from Cys β X to Cys β XII, wraps around the α-subunit, forming
a “seatbelt,” which is fastened by a disulfide bridge between Cys
residues β III and XII (Figure 2) (33, 34).
It is noteworthy that the seatbelt sequence as well as the two cys-
teines forming the fastener in β-subunits are missing in the GPB5
sequences rendering unlikely the existence of a stable GPA2/GPB5
heterodimer. In line with this view, recombinant GPA2/GPB5 het-
erodimers were evidenced by SDS-PAGE and Western blotting
only after chemical cross-linking (6, 42, 43) indicating that that
the recombinant GPA2/GPB5 heterodimer is highly unstable.
It is tempting to postulate that GPA2/GPB5 heterodimerization
is required for bioactivity as it is the case for GPH α and β sub-
units. The princeps paper (6) described thyrostimulating activity
for the GPA2/GPB5 heterodimer and further studies led to the
same (44) or other proposals for GPA2/GPB5 bioactivities in mice
(45) and insects (46, 47). Nevertheless, it was not clear from these
papers whether GPA2 and GPB5 were chemically cross-linked in
GPA2/GPB5 heterodimers used in the bioactivity studies. Thus,
it cannot be ruled out that GPA2 and/or GPB5 exert biological
functions of their own (48, 49).
Cooperative folding
The thermodynamics of GPH subunits combination has been
studied by microcalorimetry and the loss of cooperative folding
was observed only at high T m, i.e., above 70°C (50). Short-term
incubations (5 min) of different GPHs at temperatures between
4 and 86°C followed by sandwich ELISA to detect residual het-
erodimeric molecules, led to similar data (51). The conservation
or restoration, of the 3D structure at fairly high temperatures was
also confirmed by measuring residual bioactivity in cell-culture
assays.
These data indicate that the presence of one cystine-knot in
each of the two subunits together with the fastened β-subunit
“seatbelt” around the α-subunit, ensure very stable tertiary qua-
ternary structures even if it has been shown to be highly mobile
by hydrogen isotope exchange of peptide protons (35).
Kinetics and equilibrium of seatbelt fastening
The β-subunit “seatbelt” around the α-subunit fastened by the β
III–XII bridge does not influence the K d of the subunits combi-
nation (~10−6 M) but considerably lowers the rate of subunits
dissociation at physiological hormone concentration (~10−11–
10−9 M). The two disulfide bridges in the seatbelt,β III–XII (latch)
and β X–XI (tensor) appear to be involved in its opening and
closing during the heterodimer αβ formation in the endoplasmic
reticulum (52–54). Indeed, in the presence of a mixture of oxidized
and reduced glutathione mimicking the endoplasmic reticulum
redox potential, the dissociation rate of subunits is considerably
accelerated. In contrast, at the much more oxidizing redox poten-
tial corresponding to that of serum, the seatbelt remains fastened
and the dissociation rate of subunits is extremely slow (40).
Therefore, the hormone remains dimeric, and active, dur-
ing its time of presence in the circulation even if its K d is
unfavorable (1000–100,000-fold higher than hormone circulatory
concentrations).
It is important to point out that GPB5 protein sequences
derived from their gene sequences lack the polypeptide portion
forming the “seatbelt” as well as the two cysteine residues (III and
XII) forming the “seatbelt fastener” (4, 55) in all GPH β sequences.
This argues against the existence of stable secreted GPA2/GPB5
heterodimers (38, 48).
POLYSACCHARIDE PART
The mammalian GPHs contain from 15 to 45% saccharide in mass.
Polysaccharide chains are only N-linked in most of these hormones
(two in α and one or two in β; Figure 2) (13). However, a few of
them (hCG, eCG, and eLH) also possess O-linked saccharides on
their CTP extension in their β-subunits (13, 56) (Figure 2). These
sugar moieties confer high solubility, increase apparent molecu-
lar mass in SDS-PAGE, and charge polymorphism of the GPHs.
These physico-chemical properties also convey numerous impor-
tant functional properties to them. It is therefore important to
consider them here.
N-linked saccharide chains
The positions of N-linked saccharide chains are determined pri-
marily by the presence of potential N-glycosylation amino-acid
sequences (Asn–X–Ser/Thr). Saccharide chains are transferred
“en bloc” in the endoplasmic reticulum to these Asn residues
in the polypeptide chains during the course of their translation.
At this step, the N-linked saccharide chains are of the imma-
ture type, i.e., high-mannose and glycosylated. Interestingly, these
high-mannose type N-glycans have been described to possess
chaperone-like function during protein folding in endoplasmic
reticulum (57) and accordingly they facilitate correct disulfide
bond pairing (58). Correct folding is assessed by a quality con-
trol system consisting of chaperone proteins such as calnexin, BiP,
and/or Grp94 (59). This quality control also involves the removal
of the three glucose residues from these chains before the transfer
to the Golgi apparatus.
Maturation of the N-linked chains then occurs in the Golgi
apparatus. It consists in partial mannose removal by two man-
nosidases, addition of GlcNAc, Gal, and sialic acid residues by
specific enzymes. The enzyme assortment in different cell types
can differ so that N-saccharide chains can differ from one cell type
to the other. This is particularly obvious for equine LH and equine
CG that are encoded by the same α- and β-subunit genes.
These hormones are synthesized in the pituitary and placenta
respectively and although they share the same polypeptide chain
sequences, they exhibit largely differing sugar moieties (56). The
N-saccharide chains are of complex or hybrid types and possess
one to four antennas which are either completed up to a terminal
sialic acid residue or not.
Concerning GPA2 and GPB5, only recombinant molecules
and no natural ones have been available for structural studies.
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Therefore, it is possible to spot potential N-glycosylation sites
in their sequences but the presence or absence of saccharide
chains at these sites can only be checked in proteins synthesized
in heterologous systems (CHO, HEK, Sf9 cells). The analysis of
GPA2 sequences shows the presence of two potential glycosyla-
tion sites at the same locations in vertebrates and the urochor-
date Ciona intestinalis and of only one at a completely different
location in the cephalochordate Branchiostoma and in proto-
stomes. This observation reinforces the view that among chor-
dates, urochordates are phylogenetically closer to vertebrates than
cephalochordates (60). Concerning GPB5, there is one potential
N-glycosylation site in all the analyzed deuterostomes (mam-
mal vertebrates, Ciona protochordate, Strongylocentrotus purpu-
ratus echinoderm) but at different locations along their respec-
tive amino-acid sequences. By contrast, none was found in the
protostome sequences.
O-linked saccharide chains
O-linked saccharides are found in GPH heterodimers possessing a
CTP at the C-terminus of their β-subunits (hCG, eCG, and eLH).
Four O-linked saccharides are found in the hCG CTP whereas
as much as twelve of them can be found in eLH and eCG CTPs.
The numerous O-saccharides found in the CTP are thought to
impede compact folding of the polypeptide chain and to keep it
extended (61).
The α-subunit is synthesized in excess relative to the β-subunits
in the pituitary, and interestingly, it has been found that the excess
free α molecule partly undergoes an O-glycosylation at its Thr43
residue (51, 62–65). For hCG, this O-glycosylation at Thrα43 is a
late event in the secretory pathway that occurs in the Golgi appa-
ratus whereas αβ combination occurs earlier in the endoplasmic
reticulum and therefore O-glycosylation of free α plays no role in
the heterodimer assembly.
Interestingly, the free α molecule has been found to play
paracrine roles in the pituitary and the placenta (63, 66–70).
The molecular compositions of O-linked saccharides are vari-
able (71). Some of them are composed of only three saccharide
units whereas others are extremely long with poly-lactosamine
extensions. These long extensions in addition to the unfolding
effect of multiple O-saccharide sites on the polypeptide chain are
responsible for the high apparent molecular weights of the CTPs
in hCG and eCG.
Isoforms
The differences in their number of antennas and in their com-
pletion render N-saccharide chains extremely heterogeneous in
terms of mass and charge. Probably hundreds of hFSH isoforms
might exist due to all possible variants of their four N-saccharide
chains (72). The number of potential isoforms is even higher in the
case of GPHs with both N- and O-saccharide chains such as hCG,
eCG, and eLH but less variability was observed in hCG N-linked
carbohydrates than in those in hFSH.
Due to this mass and charge heterogeneity of their saccha-
ride chains, GPHs exhibit an important polymorphism in elec-
trophoresis or chromatofocusing. Such a large polymorphism
makes the physico-chemical characterization of GPH preparations
very difficult. This is true for natural as well as for recombinant
hormones which must be produced in eukaryotic cells in order to
be glycosylated.
Polymorphism due to size and charge heterogeneity of their
saccharide moieties has also been found to vary as a function of
physiological situations (menstrual cycle, gender, age) (73, 74) and
occasionally as a consequence of pathological situations.
In the case of TSH, it has been recently reported in the mouse
that the hormone produced by the pituitary pars-distalis (PD-
TSH; ~35 kD) essentially bears biantennary and sulfated N-linked
carbohydrate chains whereas that produced by the pituitary pars-
tuberalis (PT-TSH; ~40 kD) bears sialylated bi-, tri-, and tetra-
antennary carbohydrate chains (75). It is reported by these authors
that only PD-TSH stimulates thyroid hormones secretion whereas
PT-TSH acts only on the hypothalamus to regulate seasonal phys-
iology and behavior. The different glycosylations of these two
tissue-specific TSH isoforms are thus responsible for their differ-
ing functional properties in vivo. This difference is not attributable
to differing TSH receptors (TSHRs) in the thyroid and hypothala-
mus but to different affinities toward IgG and albumin leading to
differing spatial distributions of the two isoforms (75).
STRUCTURE AND IMMUNE PROPERTIES
Immunologic properties of GPHs have been used for a long time in
order to set up immunoassays to measure their concentrations in
blood in normal physiological conditions as well as in pathological
situations. Also, GPHs can promote the production of antibodies
that can adversely affect their function. It is thus of interest to
consider these properties for a better understanding of their phys-
iological roles and in view of a better control of their activity in
clinical situations where they are injected to patients.
For the setting-up of immunoassays, it is important to raise
antibodies that can distinguish the different GPHs. Therefore,
these antibodies are most often directed against the specific β-
subunits. Nevertheless, it is often more efficient to raise antibodies
against the heterodimer and to select either those that are spe-
cific of the conformation taken by the β-subunits when associated
with the common α-subunit or those that recognize epitopes con-
tributed by both subunits in the heterodimer. The free α-subunit
is not very immunogenic but a number of antibodies against the
heterodimers recognize epitopes in the associated α-subunit.
Monoclonal antibodies against each subunit are particularly
valuable for the setting-up of sandwich ELISAs that specifically
detect the heterodimers and differentiate them from free subunits.
HALF-LIFE AND ELIMINATION OF GONADOTROPINS FROM
CIRCULATION
The contribution of carbohydrate chains to GPHs half-lives has
been known for a long time (76–78). Their size and charge both
contribute to their maintenance in the circulation. There are
two main routes of elimination of gonadotropins from blood:
liver capture (78) and more prominently kidney glomerular
filtration (79–81).
For bulky plasma glycoproteins, half-life is essentially deter-
mined by their hepatic capture (76). Indeed, the -Gal-NANA end
of N-saccharide branches can more or less rapidly be desialy-
lated so that the Gal residue becomes exposed and recognized
by the hepatic Gal receptor (82). This leads to removal of the
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glycoproteins from circulation. Experiments in which hepatic cir-
culation in piglets is partly bypassed from the hepatic portal vein
to the vena cava do not show any significant increase in LH half-life
(79). It is therefore likely that the liver is not the most important
route of GPH elimination from circulation. The apparent mol-
ecular weights of GPHs are far below the glomerular filtration
limit (~60 kD) and therefore they are readily eliminated through
urine (except eCG). The high concentrations of bioactive hCG
in pregnant women’s urine and of bioactive LH and FSH in
post-menopausal women’s urine clearly demonstrate that these
hormones are readily filtrated through renal glomerulus without
major alteration of their structure. Accordingly, the half-lives are
extremely short (5–30 min) for GPHs without CTP such as hFSH
and hLH.
Also in keeping with this, a mutated recombinant hFSH with
four additional N-linked glycan chains was found to exhibit a
longer half-life and consequently a higher in vivo activity (83).
Nevertheless, liver mannose receptors appear to be involved in the
removal from circulation of glycoprotein with glycans terminated
by β1,4-linked GalNAc-4-SO4 such as in LH mainly (84, 85).
Placental GPHs possessing a CTP with long O-carbohydrates
exhibit longer half-lives (1.5–2.5 days) than pituitary GPHs with-
out CTP (5–30 min). Indeed, the hydrophilic long saccharide
chains borne by the CTP are very bulky and negatively charged
because of their terminal sialic acid residues. These properties lead
to lowered glomerular filtration because of the size and negative
charges of glomerular pores. This explains why eCG which pos-
sesses the greatest and most acidic saccharide chains on its CTP
is not found in urine in contrast to LH, FSH, and even hCG as
mentioned above.
This unique property of βCTP has been exploited by fus-
ing hCG βCTP to the hFSHβ subunit sequence in recombinant
hormones in order to increase its half-life in circulation (86–
88) (Figure 3). In further works, βCTP was used as a tether
between subunits to produce various single-chain GPHs (51,
89–93).
MOLECULAR MECHANISMS OF ACTION OF GLYCOPROTEIN
HORMONES
The very first step in GPH action is their binding to specific recep-
tors (GPHRs) at the plasma membrane level of gonadal cells.
GPHRs are seven transmembrane domain (7-TMD) receptors
with a very large extracellular domain (ECD) containing numer-
ous leucine-rich repeats (LRR) (94) with a horseshoe shape that
accommodate GPH binding.
Following high-affinity and specific binding with the recep-
tor’s ECD, an interaction with the 7-TMD must occur to pro-
mote a transconformation that is detected by the intracellular
partners, essentially the heterotrimeric G-protein Gs but also, in
certain situations, other pathways (95).
BINDING TO SPECIFIC RECEPTORS
In spite of their respective large similarities, GPHs specifically
interact with their cognate GPHRs. This is true at least when con-
sidering hormones and receptors from the same species. Indeed,
eLH and eCG are known to exhibit FSH activity in addition to their
LH activity in all species except their own (horse) and chicken.
Moreover, hCG exhibits low but significant TSHR binding activity
in addition to its strong LHR binding activity even in its own
species (human).
FIGURE 3 | Structure of wild-type and long-acting hFSHs and their
therapeutic use. The upper panel schematically shows the structure of
wild-type hFSH and hFSH fused with the hCGβ CTP that confers extended
half-life to the heterodimer in the circulation. The lower panel shows the
usage of wt-hFSH injected daily for 1week and then optionally for 1–3 days
more depending of follicular development. LA-FSH is injected once and the
treatment is optionally continued with one to three daily injections of wt-FSH
if required.
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It has been known for a long time now that both the GPH com-
mon α- and the specific β-subunits participate in receptor binding
(95, 96). It appears from X-ray diffraction studies of the FSH–FSH
ECD complex that the β-subunit’s seatbelt and the two neigh-
boring regions in the α-subunit form the hormone surface that
interacts with the receptor’s ECD (36, 97, 98). The involvement
of the common α-subunit in receptor binding suggests an impor-
tant similarity in the interaction mechanisms. From comparative
data, we were the first to propose a long time ago the “negative
specificity” model. In this model, the α-subunit contribution to
binding is only high-affinity whereas that of the β-subunit’s seat-
belt is to control specificity by inhibiting hormone binding to
the “wrong” receptors (99, 100). It is interesting to point out that
GPB5 that lacks this seatbelt region not only would lead to unsta-
ble GPA2/GPB5 heterodimers but also would lack this specificity
mechanism leading to their potential binding to all GPHRs. Since
TSHR is the receptor with the lowest specificity as it also binds
hCG (101, 102), this may explain why GPA2/GPB5 binds only to
it and not to FSHR and LHR.
The crystal structure of the FSHR ECD in complex with FSH
(36, 95, 103) indicates that FSH establishes contacts with some
β-strands of the concave inner surface of the leucine-rich repeat
domain (LRRD) of the ECD (94). This paper also report dimer-
ization of the FSH/FSHR ECD complex in agreement with previ-
ous data showing that recombinant GPHRs functionally defective
either in their ECD or 7-TMD can complement and transduce
the hormonal signal when co-expressed in the same cells (104,
105). More recent data suggest a trimerization of FSHR upon
FSH binding (106) and an activation mechanism involving a FSH
transconformation allowing its direct interaction with the FSHR
sulfated Tyr residue at position 335 (95).
In the TSHR, the hinge region does not only serve for sta-
bilizing the receptor ECD LRRD but it also participates in TSH
binding (107).
The position of certain N-saccharide chains can affect speci-
ficity of binding. Indeed, it has been shown that eCG and eLH
do exhibit FSH activity in all species tested so far but not in their
species of origin (horse) and also very weakly in chicken (108). As
mentioned above, the presence of an extra saccharide chain at the
same position (Asn 268) in the FSH receptors ECDs from these
two species might explain why LH specificity of eLH and eCG only
exists in these species.
It has been reported that the GPA2/GPB5 heterodimer binds
to the TSHR in mammals (6, 42, 109) but the receptors for
GPA2/GPB5 or GPA2 and GPB5 independently in invertebrates
are obviously not TSHR but are suspected to be GPHR ancestors
and thus to belong to the GPCR family exhibiting a LRRD. In
Drosophila melanogaster, the DLGR1 GPCR with LRRD has been
reported to bind human GPA2/GPB5 (43). The LGR1 receptor
gene has also been identified in the mosquito Aedes aegypti where
this receptor has been proposed to regulate ion-transport across
the hindgut (47). In Caenorhabditis elegans, only one GPCR gene
with LRRD has been identified (fsh-r1) that exhibits the high-
est similarity with FSHR among mammalian GPHR and plays
a role in innate immune response (110). In this species, genes
apparented to GPA2 (flr-2) and GPB5 (flr-5) were identified and
might regulate FSH-R1 in the neural control of intestinal functions
(49), maybe including intestinal ion-transport and/or intestinal
immune defense.
TRANSMEMBRANE SIGNAL TRANSDUCTION
The transmembrane (TM) signaling by GPHRs is due to the
transconformation of their 7-TMD upon hormone binding to
their ECD and subsequent interaction with the extracellular loops
and/or extracellular amino-acids of their 7-helical TM sequences.
Precious structural information has been gained from the crys-
tallographic studies of hormone–receptor ECD complexes men-
tioned above. No such information is available concerning the
whole receptor and thus concerning ECD/7-TMD interaction
upon GPH binding.
It had been shown a long time ago that LH is able to activate its
receptor deprived of its ECD but with a low K d (10
−7 M instead of
10−10 M approximately) (111). This result suggests that the hor-
mone ligand itself can directly contact the 7-TMD albeit with low
affinity and promote its activating transconformation. The ECD
might thus “catch” the hormone at very low physiological con-
centration and greatly favor its interaction with the 7-TMD so
that transconformation of the latter can occur. In this first model,
the hormone would thus be sandwiched between the ECD and
the 7-TMD.
Determination of the 3D structure of GPCR 7-TMD has suc-
ceeded in only a limited number of them giving a static view
yet they are expected to be highly dynamic and to assume dif-
ferent conformational states. These different conformations are
functionally important as they are stabilized through the bind-
ing of the receptor with agonists or antagonists, with another
receptor (dimerization) or with downstream partners (proteins
G or others). These trans-conformations between inactive and
active states affect mainly the relative orientations and distance
of the seven TM sequences that can be detected intracellularly
by the downstream partners (112). Repulsive separation of TM3
and TM6 in the TSHR 7-TMD is linked to receptor constitutive
activation (113).
Glycoprotein hormone receptors are GPCRs and as such con-
vey their signaling information mainly through interaction with
heterotrimeric G-proteins mainly Gs but also Gi or Gq. Upon stim-
ulation by their cognate GPH, GPHRs interact with the α-subunit
in Gs protein and promote the exchange of GDP for GTP in this
α-subunit. The αs-GTP subunit then separates from the βγ sub-
units complex and interacts with the adenylate cyclase to increase
its activity and thus intracellular cyclic AMP concentration (114).
This very general mechanism will not be detailed here.
INTRACELLULAR SIGNALING DOWNSTREAM TO GPHRs
The main partner GPHRs is the heterotrimeric Gs protein that
stimulates membrane adenylate cyclase activity and consecutively
leads to intracellular increase in cyclic AMP and thus to protein
kinase A (PKA) stimulation. Specific phosphorylation of numer-
ous proteins on threonine and/or serine residues is catalyzed by
PKA. Among these proteins, there are transcription factors and
various metabolic enzymes and structure proteins so that the bio-
logical responses to GPHs are genomic and/or metabolic and/or
morphological. Thorough description of these cellular responses
would be interesting but outside the scope of the present chapter.
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We focus here on such issues only for examples related to the
structure of GPHs or GPHRs.
After their phosphorylation by GRK, GPHRs recruit arrestin
that promotes desensitization of the Gs pathway. In addition,
arrestin acts as a scaffolding protein and recruits MAPKKK (Raf),
MAPKK (MEK), and MAPK (ERK) and stimulates this pathway. It
is thus interesting to note that arrestin do not act solely for arresting
Gs signaling but also to initiate another signaling pathway (115).
Therefore, arrestin is not only an interruptor but a commutator in
signaling pathways downstream of GPHRs stimulation.
GPHR DESENSITIZATION AND INTERNALIZATION
Upon stimulation of GPHR by their cognate GPH, activated αs-
GTP of the Gs protein separates from the βγ subunits complex.
This complex recruits a GRK (GPCR kinase) that can in turn phos-
phorylate the activated GPHR at one or several specific locations
in its intracellular sequences. These phosphorylated residues are
target sites for arrestin that then interferes with the receptor–Gs
protein interaction and thus desensitizes this pathway. In addi-
tion, as indicated before, arrestin also acts as a scaffolding protein
that recruits MAPKKK, MAPKK, and MAPK thus initiating the
stimulation of this pathway. Downstream the LH-induced LHR
activation, it is the arrestin-3 isoform that is involved in the MAPK
cascade activation in MA-10 cells (116).
Upon further hormone stimulation, receptor internalization
occurs in addition to desensitization. This step is promoted by the
arrestin-induced clathrin-coated pits that engulf GPHRs intra-
cellularly into the endosomes. In the case of the TSHR, it is
the arrestin-2 isoform that promotes internalization through this
pathway (117). The fate of the internalized receptors is either
degradation or recycling back to the plasma membrane in vari-
ous proportions. The monomeric G-proteins Rab are responsible
for this trafficking by promoting vesicle budding and fusion. These
Rab proteins are GTPases like the Gs α-subunit: they are activated
by exchanging GDP for GTP under the action of a guanosine
nucleotide exchange factor (GEF) and they are inactivated by
hydrolyzing this GTP back to GDP.
Their GTPase activity permits their auto-inactivation which
is enhanced by GTPase activating proteins (GAPs). Among the
60 Rabs known so far, Rab5a which is located to early endo-
some, mediates GPCR internalization. Indeed, Rab5a facilitates
LHR internalization but it also favors its degradation and inhibits
its recycling (118).
PHYSIOPATHOLOGICAL CONDITIONS AND CLINICAL
CONSEQUENCES
The most numerous diseases involving gonadotropins are due
to diminished (congenital hypogonadotropic hypogonadism) or
excessive (adenomas) levels of secretion. The first are due to
fetal defect in GnRH neuron migration, or a defect of pituitary
development or from a functional defect of the hypothalamic–
pituitary axis between GnRH neurons and gonadotrope cells (Kall-
mann syndrome). The latter arises following the development of
LH-, FSH-, or TSH-secreting pituitary adenomas (119). The study
of these conditions is beyond the scope of the present paper as
they are not related to the structure of gonadotropins or of their
receptors.
Natural mutations in GPH genes and in their receptors’ genes
are either activating (gain of function) or inhibiting (loss of func-
tion). The former are expressed as a dominant trait, thus in the
heterozygous state, whereas the latter are only expressed when
biallelic. In addition, some mutations affect internalization and/or
degradation of GPHRs.
PATHOLOGICAL CONDITIONS DUE TO HORMONE STRUCTURE
MODIFICATIONS
Pathological conditions due to mutations in gonadotropin or thy-
rotropin gene coding sequences and hence to modifications in
their polypeptide structure are fairly rare. However, some patho-
logical conditions are due to or are related with modifications in
the saccharide side chains.
For example, trophoblastic cells from trisomy 21 pregnancy
produce hyper-glycosylated forms of hCG with low biological
activity (120). Detection of hCG variants has also been shown
to be related to various malignancies in human (121).
Abnormal stimulation of TSHR by hCG during pregnancy has
also been described. A small proportion of these patients have
clinical hyperthyroidism, termed gestational thyrotoxicosis (102).
They either secrete a variant of hCG with increased thyroid-
stimulating activity or their TSHR has increased affinity for hCG.
A unique family with recurrent gestational hyperthyroidism asso-
ciated with hyperemesis gravidarum was found to have a mutation
in the ECD of the TSHR that made it responsive to normal levels
of hCG (122).
While mutations of gonadotropin and TSH genes in human are
exceedingly rare, genetic alterations of their respective receptors
are more frequent. These mutations can lead either to constitu-
tive activation of the receptors or to their inactivation, i.e., their
inability to respond to their cognate hormone for various reasons.
PATHOLOGICAL CONDITIONS DUE TO FSHR
Inactivating mutations
Inactivating mutations of FSHR gene, in women, are generally
associated with primary ovarian insufficiency. Numerous inacti-
vating FSHR mutations have been described such as Ala189Val
in the FSHR ECD leading to hypergonadotropic hypogonadism
with no or weak response to FSH (123, 124). A Pro519Thr muta-
tion in the second intracellular loop of the 7-TMD was asso-
ciated to elevated serum FSH concentration, low estrogen and
inhibin concentrations, and hypoplastic uterus and ovaries. The
inactivity of the receptor was found not to be due to defect in
its signal transduction ability but to its intracellular trapping,
and therefore to its absence at the cell surface. In patients with
such total loss of FSHR function, there is no passage from pri-
mary to secondary follicles (125) and this block of course causes
infertility.
Activating mutations
In contrast to the numerous inactivating mutations in FSHR, only
one example of activating mutation has been described in human:
Asp567Gly in the third intracytoplasmic loop (126). The D550G
mutation in the FSHR 7-TMD has been recently shown to uncou-
ple the link between internalization and degradation of hFSH. It
is therefore expected to be more efficiently recycled.
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Extragonadal expression
In addition to FSHR structure modifications due to mutations,
diverse pathologies are a consequence of its anomalous extrag-
onadal expression. FSHR is normally expressed in extragonadal
reproductive tissues such as placenta (127) but also in the endothe-
lial cells associated with a diverse range of solid tumors (128).
Genitourinary malignancies were strongly represented (prostate
adenocarcinomas, urothelial carcinomas, renal cell carcinomas,
and seminomas). The ubiquitous nature of FSHR in tumor blood
neovasculature suggests a biological role in human solid tumors
possibly through induction of vascular endothelial growth fac-
tor (VEGF) in granulosa cells. FSHR has also been shown to be
expressed in normal prostate tissue but at significantly lower levels
than in prostate cancer.
The presence of the Ser680 FSHR isoform in Taiwanese women
was found to be associated to a lower occurrence of endometriosis
(129). This suggests the presence of functional FSHR in invading
endometrial cells.
PATHOLOGICAL CONDITIONS DUE TO LHR STRUCTURE MODIFICATIONS
Activating and inactivating mutations in LHR with very different
phenotypic effects have been identified. Inactivating mutations
in the LHR are responsible for male pseudohermaphroditism
or Leydig cell hypoplasia in individuals with 46 XY karyotypes,
characterized by a predominantly female phenotype. Activating
mutations in the LHR are responsible for precocious puberty due
to its constitutive activity in the absence of hormone.
Inactivating mutations
Inactivating mutations of LHR gene most often affect XX individ-
uals whose families also include cases of male pseudohermaphro-
ditism. Clinically, these women suffer from primary amenorrhea
but with normal development of breast and pubic hair.
Naturally occurring LHR mutant without the polypeptide
sequence encoded by exon 8 causes Leydig cell hypoplasia due to
the loss of hormone-binding ability. The LHR mutant lacking exon
9 was found not to be addressed to the plasma membrane thus also
leading to insensitivity to the hormone. Recently, a novel cryptic
exon (exon 6A) was found in LHR gene (130) that leads to the
synthesis of an incomplete mRNA variant encompassing exons 1–
6–6A (6A terminal variant). A mutation in exon 6A (A557C) leads
to an overexpression of this shortened mRNA as well as that of an
mRNA including exons 1–6–6A–7–11 (6A internal variant) in Ley-
dig cells leading to an insufficient amount of full-length mature
LHR at the cell surface. Like inactivating mutations in the LHR
coding sequence, the overexpression of LHR mRNA including the
6A exon is thus responsible for male pseudohermaphroditism or
Leydig cell hypoplasia (130). These three examples among many
others indicate that the insensitivity of LHR to its cognate hor-
mones LH and HCG may have very different causes (binding
deficiency, intracellular trapping, or transcription inhibition).
Activating mutations
Activating mutations in the LHR gene are one of the most com-
mon mutations found in the GTHR genes. These mutations pro-
mote precocious puberty in boys but no obvious phenotype in
females (131).
There are no reports of naturally occurring activating muta-
tions in the ECD although, engineered mutations of a serine
residue in the hinge region of LHR result in constitutive activ-
ity of receptors expressed in recipient cells (132). One of the most
common activating mutations is the missense mutation D578G in
TM6 of the TMD. Another mutation at the same position (D578H)
was found to be highly activating. To date, there is no report of
women with a D578H mutation; this mutation has appeared only
as a somatic mutation restricted to Leydig cell tumors in boys
ranging in age from 5 to 8 years, suggesting that this particular
mutation is incompatible with germ-line transmission (131).
Another constitutively activating mutation in the TM3 of
the hLHR (L457R) has been identified in only one boy with
gonadotropin-independent precocious puberty (133). Interest-
ingly, the amino-acid in this location forms a salt bridge with
the amino-acid in position 578 that is also prone to activating
mutations as described above. The L457R mutation in LHR has
also been found to diminish lysosomal degradation of the recep-
tor and this could also contribute to its constitutive activity by
prolonging the duration of signaling (134).
The N312S mutation of LHR does not lead to any functional
effect but has been shown to be moderately but significantly
related to increased breast cancer (135). The reason of this link
is unknown.
PATHOLOGICAL CONDITIONS DUE TO TSHR
Activating mutations
Activating mutations of the TSHR are rare. Nevertheless, an het-
erozygous substitution in exon 10 (Ile568Thr) leads to neonatal
thyrotoxicosis without anti-TSHR antibodies production (136).
Likewise, a Leu665Phe mutation in TSHR TM helix 7 leads to
non-autoimmune hyperthyroidosis (137).
Inactivating mutations
Inactivating mutations in human TSHR also exist in a few
occurrences. For example, the Gln489His mutation in the first
extracellular loop, leads to hypothyroidism (138).
TSHR autoantibodies
Graves’ disease (elevated thyroid hormone levels and low to unde-
tectable TSH) is a leading cause of hyperthyroidism worldwide. It
arises from the action of TSHR stimulating autoantibodies. TSHR
autoantibodies are either stimulating (cAMP/PKA/CREB and/or
AKT/mTOR/S6K signaling cascades) or inhibiting TSH effects,
or neutral autoantibodies that induce thyroid cell apoptosis via
reactive oxygen species (ROS) generation.
In contrast to the gonadotropin receptors FSHR and LHR,
TSHR ECD is maturated by proteolysis and is connected to
the TM domain through a disulfide bridge (139). The unshed
TSHRs or disulfide cleaved soluble ECD forms and/or TM forms
might be much more immunogenic than the functional maturated
receptors with SS-bridged subunits.
GPA2/GPB5 binding
Since GPA2/GPB5 heterodimer has been proposed to bind to
TSHR in vertebrates, it is interesting to point out that GPB5−/−
mutant mice exhibit transient hypothyroxinemia (109) whereas
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mice overexpressing GPB5 show a resistance to diet-induced obe-
sity (45). The involvement of defects in GPA2, GPB5, or TSHR
should thus eventually be taken in consideration in thyroid axis
pathologies.
CONCLUSION AND PERSPECTIVES
Because of their implication in important physiological functions
and their structural complexity, GPHs and their receptors remain
a difficult and active field of investigation. The complexity of their
structure makes the pharmaceutical production and control of
recombinant hormones a heavy task. For example, hFSH with a
fused hCGβ CTP (Figure 3) which is now on the market (cori-
follitropin; Elonva®) in an increasing number of countries clearly
exhibits a longer half-life that permits to diminish the number of
injections to the patients. Nevertheless, there is a possible risk of
ovarian hyperstimulation in some of them.
Since GPCRs are the main targets of pharmaceuticals, it can
be envisioned that synthetic small-molecular weight drugs will
be, sooner or later, available to finely tune the activation of LHR
and FSHR for fertility treatments. A number of such molecules
have already been synthesized and tested (140–144) and structure
modeling (145, 146) is expected to be particularly helpful in the
molecular design of new drugs of this type.
Concerning their ancestors, GPA2 and GPB5, their putative het-
erodimerization is still a matter of debate as well as their biological
activities either on their own or after combination.
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